

Resource Summary Report

Generated by PRECISE-TBI on Aug 1, 2026

Childrens Tumor Foundation

RRID:SCR_006280

Type: Tool

Proper Citation

Childrens Tumor Foundation (RRID:SCR_006280)

Resource Information

URL: <http://www.ctf.org/>

Proper Citation: Childrens Tumor Foundation (RRID:SCR_006280)

Description: A non-profit dedicated to ending neurofibromatosis (NF) through research. It is the leading nonprofit funding source of NF research in the world. The mission of The Children's Tumor Foundation is to: * Encourage and support research and the development of treatments and cures for neurofibromatosis types 1 and 2, schwannomatosis, and related disorders (hereafter collectively referred to as NF); * Support persons with NF, their families, and caregivers by providing thorough, accurate, current, and readily accessible information; * Assist in the development of clinical centers, best practices, and other patient support mechanisms (but not including direct medical care) to create better access to quality healthcare for affected individuals; and, * Expand public awareness of NF to promote earlier and accurate diagnoses by the medical community, increase the non-affected population's understanding of the challenges facing people with NF, and encourage financial and other forms of support from public and private sources. Through the implementation of the Foundation's research initiatives, progress is being made on all fronts and for all types of NF; from discovery studies understanding the molecular signaling deficits that cause the manifestations of NF to the growth of preclinical drug screening initiatives and the emergence of a growing number of clinical trials. The Foundation advances research through strategically integrated programs that speed therapies from the lab to the patient.

Abbreviations: CTF

Synonyms: Children's Tumor Foundation, Children's Tumor Foundation: Ending Neurofibromatosis Through Research

Resource Type: institution

Keywords: child, award, grant, contract, drug discovery, clinical

Related Condition: Neurofibromatosis, Schwannomatosis

Resource Name: Childrens Tumor Foundation

Resource ID: SCR_006280

Alternate IDs: Wikidata: Q5098233, nlx_151890, ISNI: 0000 0004 5906 2417, grid.421144.6, Crossref funder ID: 100001545

Alternate URLs: <https://ror.org/01hx92781>

Record Creation Time: 20220129T080235+0000

Record Last Update: 20260725T190617+0000

Ratings and Alerts

No rating or validation information has been found for Childrens Tumor Foundation.

No alerts have been found for Childrens Tumor Foundation.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Vasiljevski ER, et al. (2021) L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial. American journal of medical genetics. Part A, 185(10), 2976.

Chang LS, et al. (2021) Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PloS one, 16(7), e0252048.

Vasiljevski ER, et al. (2020) Evaluating modified diets and dietary supplement therapies for reducing muscle lipid accumulation and improving muscle function in neurofibromatosis type 1 (NF1). PloS one, 15(8), e0237097.

, et al. (2018) Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PloS one, 13(6), e0197350.

Allaway RJ, et al. (2018) Cutaneous neurofibromas in the genomics era: current understanding and open questions. British journal of cancer, 118(12), 1539.

Martinez M, et al. (2017) Gene signature associated with benign neurofibroma transformation to malignant peripheral nerve sheath tumors. PloS one, 12(5), e0178316.

Jahanshahi M, et al. (2016) The Hippo Pathway Targets Rae1 to Regulate Mitosis and Organ Size and to Feed Back to Regulate Upstream Components Merlin, Hippo, and Warts. PLoS genetics, 12(8), e1006198.

Miller SJ, et al. (2009) Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO molecular medicine, 1(4), 236.

Radtke HB, et al. (2007) Neurofibromatosis type 1 in genetic counseling practice: recommendations of the National Society of Genetic Counselors. Journal of genetic counseling, 16(4), 387.